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Background: Hyperglycemia and hypoglycemia are associated with increased long-term mortality in patients with acute myocardial infarction, 
irrespective of diabetic state. Moreover, neointimal hyperplasia after coronary stent implantation is increased in the presence of suboptimal glycemic 
control. Both hypoglycemia and hyperglycemia may have a pathogenic role in endothelial dysfunction and inflammation, potential mechanisms for 
adverse outcome following percutaneous coronary intervention (PCI). The aim of this study was to evaluate the relationship between pre-procedural 
blood glucose levels and long-term outcome in patients undergoing PCI.
Methods: We prospectively enrolled 572 patients who underwent coronary stenting at our Institution. In all patients, blood glucose levels were 
measured before PCI and, according to these, patients were classified in four pre-defined groups: hypoglycemia < 80 mg/dl; euglycemia 81-
109 mg/dl; mild hyperglycemia 110-125 mg/dl; hyperglycemia > 126 mg/dl. Primary end point was the occurrence of clinically driven in-stent 
restenosis, defined as stenosis of at least 50% of the luminal diameter.
Results: After a median of 15±8 months, incidence of in-stent restenosis was significantly higher in patients with hypoglycemia (30%) and 
hyperglycemia (17%) compared with the euglycemic (10 %) and mild hyperglycemic groups (11%) (p for trend = 0.007). Incidence of death and 
myocardial infarction was not different between the four groups. All patients with angiographic evidence of in-stent restenosis were treated with re-
PCI. Kaplan Meier curve showed the worst 36-month event-free survival for patients with pre-procedural blood glucose levels ≤ 80 mg/dl compared 
with the other groups (Log rank P=0.0004). Multivariate analysis confirmed hypoglycemia as an independent predictors of in-stent restenosis.
Conclusions: In patients undergoing PCI, hypoglycemia and hyperglycemia are associated with increased incidence of in-stent restenosis. These 
results suggest that optimal glucose control remains an important target in diabetic and non-diabetic patients undergoing PCI.
